WASHINGTON, July 11, 2012 – Michael D. Petty, the former vice president of development and regulatory law at Amgen Inc., has joined the FDA and life sciences practice of King & Spalding as a pharmaceutical regulatory partner in its Washington, D.C., office, the firm announced today.
“With a strong skill set, extensive experience and deep technical expertise in pharmaceutical and biotechnology regulatory matters, Michael brings additional strength to our team,” said Edward M. Basile, chair of King & Spalding’s FDA and life sciences practice. “We welcome Michael to King & Spalding and look forward to the contributions he will make as we continue to expand our pharmaceutical and biotech practice.”
During his six-year tenure at Amgen, Petty was responsible for building its regulatory law department and for legal support and strategy in the areas of corporate research and development operations for pharmaceuticals, biotechnology products and medical devices; corporate regulatory affairs; scientific affairs; global health economics; pharmaceutical, biotechnology and medical device issues; and worldwide compliance and business ethics.
Previously, Petty was a partner in the FDA regulatory practice at Ropes & Gray LLP and served as associate chief counsel for enforcement at the United Stated Food and Drug Administration, where he handled a variety of civil, criminal and administrative enforcement matters. He attended the University of North Carolina, where he received a J.D. degree from its School of Law, a master’s in public health from its School of Public Health and a B.A. degree, with honors.
“I have always been impressed with King & Spalding’s work and the depth and breadth of its experience in FDA regulatory matters, and government and congressional investigations,” said Petty. “Having made the decision to return to private practice, I believe the firm, with its talented team of FDA lawyers, is a natural fit for me.”
About King & Spalding
Celebrating more than 125 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 800 lawyers in 17 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.